Dr. Joachim Greuel is the latest expert to join the Life Sciences Advisory Board at FCF Fox Corporate Finance GmbH

Complementing the leading industry experts already advising the Munich-based corporate financing specialist, Dr. Joachim Greuel joins FCF’s Life Sciences Advisory Board.

Munich, January 18, 2021

FCF Fox Corporate Finance GmbH (“FCF”) welcomes yet another renowned expert to its Life Sciences Advisory Board. Dr. Joachim Greuel will provide valuable support and guidance to the corporate finance specialist in all aspects of life sciences.

As Managing Director and co-founder of BioScience Valuation BSV GmbH (“BSV”), a leading global life sciences valuation firm, Dr. Joachim Greuel helps clients from the healthcare sector assess the value of new pharmaceutical projects and present a compelling case to potential investors. Dr. Greuel began his career as the head of a research team at Bayer AG and served as Investment Manager at the Swiss-based venture capital fund NMT New Medical Technologies before co-founding BSV.

FCF established a strategic alliance with Dr. Joachim Greuel and BSV in May 2020 to give clients professional, reliable support with their valuations in funding deals and beyond.

Dr. Mathias Schott, Director of Life Sciences at FCF is delighted with the new addition: “Dr. Greuel and his team at BSV impressed us with their deep scientific and medical expertise, which has produced real benefits for our firm over the past few months of collaboration. That makes us all the more pleased to welcome him as a new member on our Life Science Advisory Board.”

The Life Sciences Advisory Board plays a key role in FCF’s corporate strategy when it comes to life sciences financing, focusing on highly innovative companies in the Biotech and Medtech arenas.

FCF CEO Arno Fuchs explains: “We are extremely proud of the numerous skilled professionals from the life sciences ecosystem that have joined our advisory board since its founding two years ago. Together with existing Board members Dr. Alexandra Goll, Dr. Axel Polack, Claus Schalper, Prof. Dr. Horst Domdey and Enno Spillner, FCF has succeeded in bringing together expertise from capital markets and investment banking on the one hand with the science and practice-based perspective on the other. This constellation is unique in the German-speaking market and provides a strong foundation for our success in funding deals throughout Germany and increasingly across Europe.”

For more information on the Life Sciences Advisory Board, its members and their professional background, visit www.fcf.de/life-sciences/.


FCF is a specialized Investment Bank and Financing Specialist, advising public and private small/mid-market companies in the German speaking regions.

FCF focuses on four primary client segments:
  • MidCap: Medium-sized companies with sustainable business models in typical “Mittelstand” industries, such as industrial products and machinery, automotive, communications, logistics, and consumer products
  • SmallCap / Growth: Companies with revenues between €20 and €100 million and high / above average growth rates
  • DeepTech: R&D-driven companies in technology sectors, entering the commercialization stage with initial fast-growing revenues
  • Life Sciences: Highly innovative companies focusing on the development of cutting-edge biotechnology, med-tech, health-tech and pharmaceuticals solutions

FCF structures, arranges and places equity and debt capital transactions and supports its clients’ growth, IPO/Pre-IPO, acquisition and standard balance sheet (re-)financing strategies.

Founded in 2005 and headquartered in Munich, FCF has direct relationships and works with all leading German, European and international financiers, lenders and investment houses addressing German small/mid-cap companies.

Media Contact
newskontor – Agentur für Kommunikation
Julian Kerkhoff, Tel: +49-211-863949-32
Mail: julian.kerkhoff@newskontor.de

FCF Fox Corporate Finance GmbH
Maximilianstrasse 12-14
80539 München
Tel: +49-89-20 60 409-0
Fax: +49-89-20 60 409-299